SG32486G - Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease - Google Patents

Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease

Info

Publication number
SG32486G
SG32486G SG32486A SG32486A SG32486G SG 32486 G SG32486 G SG 32486G SG 32486 A SG32486 A SG 32486A SG 32486 A SG32486 A SG 32486A SG 32486 G SG32486 G SG 32486G
Authority
SG
Singapore
Prior art keywords
derivatives
disease
treatment
chronic obstructive
pharmaceutical preparations
Prior art date
Application number
SG32486A
Other languages
English (en)
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20336144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG32486(G) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Draco Ab filed Critical Draco Ab
Publication of SG32486G publication Critical patent/SG32486G/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG32486A 1978-10-20 1986-04-07 Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease SG32486G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7810946A SE7810946L (sv) 1978-10-20 1978-10-20 Metod att behandla kronisk obstruktiv luftvegssjukdom

Publications (1)

Publication Number Publication Date
SG32486G true SG32486G (en) 1989-12-22

Family

ID=20336144

Family Applications (1)

Application Number Title Priority Date Filing Date
SG32486A SG32486G (en) 1978-10-20 1986-04-07 Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease

Country Status (8)

Country Link
US (2) US4325956A (en, 2012)
EP (2) EP0045094B1 (en, 2012)
JP (1) JPS5557517A (en, 2012)
AU (1) AU529805B2 (en, 2012)
HK (1) HK71486A (en, 2012)
IE (1) IE49623B1 (en, 2012)
SE (1) SE7810946L (en, 2012)
SG (1) SG32486G (en, 2012)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810947L (sv) * 1978-10-20 1980-04-21 Draco Ab 3-alkylxanthines
SE8002910L (sv) * 1980-04-18 1981-10-19 Draco Ab 3,8-dialkylxantiner, forfarande for deras framstellning, beredning och metoder for behandling av kronisk obstruktiv luftvegssjukdom och kardiovaskulera sjukdomar
DE3127237A1 (de) * 1981-07-10 1983-01-20 Hoechst Ag, 6000 Frankfurt Magenvertraegliche arzneiformen von xanthinderivaten und verfahren zu ihrer herstellung
US4562194A (en) * 1984-07-31 1985-12-31 Warner-Lambert Company Synergistic non-steroidal anti-inflammatory compounds and compositions thereof
SE8602887D0 (sv) * 1986-06-27 1986-06-27 Draco Ab New chemical method
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
EP0407651A3 (en) * 1989-07-10 1991-08-07 J. Uriach & Cia. S.A. Use of 1,3-diisobutyl-8-methylxanthine as a bronchodilator and antiallergy agent
US5270316A (en) 1989-10-20 1993-12-14 Kyowa Hakko Kogyo Co., Ltd. Condensed purine derivatives
WO1994019351A1 (en) * 1993-02-26 1994-09-01 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
IL148366A0 (en) * 1999-08-31 2002-09-12 Univ Vanderbilt Selective antagonists of a2b adenosine receptors
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
CN1671399A (zh) * 2002-07-29 2005-09-21 Cv医药有限公司 利用a2a受体激动剂的心肌灌注显像
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
RU2007114908A (ru) * 2004-10-20 2008-10-27 Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС Применение агонистов аденозиновых рецепторов a2a
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
KR20090047499A (ko) * 2006-09-01 2009-05-12 씨브이 쎄러퓨틱스, 인코포레이티드 심근 조영법 동안에 환자의 순응성을 증가시키기 위한 방법및 조성물
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
MX2009007071A (es) * 2007-01-03 2009-10-13 Cv Therapeutics Inc Elaboracion de imagen de perfusion del miocardio.
KR20110063556A (ko) * 2008-09-29 2011-06-10 길리애드 사이언시즈, 인코포레이티드 다검출 전산화 단층 촬영법에 사용하기 위한 ａ-２-알파 수용체 길항제와 속도 조절제의 조합물
JP2016027279A (ja) * 2014-07-02 2016-02-18 日本精工株式会社 冠型保持器及びアンギュラ玉軸受

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
GB683523A (en) 1948-08-18 1952-12-03 Beecham Res Lab The manufacture of purine derivatives
GB1435916A (en) * 1972-05-11 1976-05-19 Beecham Group Ltd Pharmaceutical weight-reducing compositions
CA1077932A (en) * 1976-03-31 1980-05-20 Berlex Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents

Also Published As

Publication number Publication date
US4325956A (en) 1982-04-20
AU5187279A (en) 1980-05-01
EP0011609A3 (en) 1980-07-23
EP0011609A2 (en) 1980-05-28
JPS6340167B2 (en, 2012) 1988-08-10
EP0045094B1 (en) 1984-05-16
US4804664A (en) 1989-02-14
EP0045094A1 (en) 1982-02-03
HK71486A (en) 1986-10-03
IE791988L (en) 1980-04-20
AU529805B2 (en) 1983-06-23
JPS5557517A (en) 1980-04-28
SE7810946L (sv) 1980-04-21
EP0011609B1 (en) 1983-04-13
EP0011609B2 (en) 1988-05-11
IE49623B1 (en) 1985-11-13

Similar Documents

Publication Publication Date Title
SG32486G (en) Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
ZA804180B (en) Medicaments for the treatment of disorders in lipometabolism and their use
GB2199031B (en) Cyclodextrinclathrates of carbacycline derivatives and their use as medicinal drugs
HK41284A (en) Thio etianic acid derivatives, their preparation and pharmaceutical use
JPS5555113A (en) Oral administration medical tablet and its manufacture
DE3068803D1 (en) The use of 2-phenyltetralin derivatives, or heterocyclic analogues, in medicine and pharmaceutical compositions containing them
DE3062981D1 (en) Alkyl-urea derivatives for the treatment of lipometabolic diseases; process for their preparation, their use in medicaments for the treatment of lipometabolic disorders, medicaments containing them, process for the preparation of the medicaments, and some alkyl-urea derivatives
EP0324802A4 (en) Method for the treatment of body tissues and the administration of drugs thereto
NO171679C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-fenyl-3-(1-piperazinyl)-1h-indazoler
NZ193078A (en) Derivatives of 9-aminoalkyl-flyorene medicinal preparations
PT73061B (en) Process for the preparation of new derivatives of taurina and its pharmaceutical use
GB2057872B (en) Use of glycerylphosphoryl derivatives in the therapy of dislipaemia hepatitis and like pathological conditions and pharmaceutical compositions therefor
DE2967632D1 (en) Use of a xanthine derivate in the manufacture of a medicament
ZA855399B (en) Use of xanthine and thioxanthine derivatives for the preparation of medicaments
NL187299C (nl) Gevormde farmaceutische doseringseenheid voor het behandelen van hart- en vaatziekten.
AU3028589A (en) Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia
DE2965208D1 (en) Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
FI891210A7 (fi) Tiosulfiinihappojohdannaiset, niiden käyttö tulehdussairauksien käsitt elyyn sekä näitä aineita sisältävät lääkeaineet
PH16250A (en) Pharmaceutical composition of therapeutic value in the treatment of some shock conditions
GB2076399B (en) Process for the manufacture of novel benzazole derivatives pharmaceutical preparations containing these derivatives and their use
EG14024A (en) Pharmaceutical compositions and their use in the profyloxis and or treatment of certain diseases
NZ184158A (en) Uracil derivatives: preparation and pharmaceutical preparations
JPS539757A (en) Production of taunorbicine derivatives and pharmaceutical composition for treating tumor of human
DE2967615D1 (en) Tetrahydropyridinyl indole derivatives and their salts for use in a method for therapeutic treatment of the human or animal body and pharmaceutical compositions containing them
EP0018550A3 (en) Use of physiologically acceptable methyl donors in preparing compositions for muscular disease treatment and compositions containing these methyl donors